| abstract |
The present invention relates to a nucleic acid which codes for one or more human papilloma virus (HPV) oncoproteins and/or fragments thereof. The nucleic acid can induce an immune response after expression in a mammalian organism, which results in the destruction of HPV-oncoprotein-expressing cells and is thus suitable for the prophylaxis and/or treatment of HPV-induced illnesses, such as cervical cancer and the precursors thereof. Relative to known nucleic acid vaccines, the construct according to the invention is characterized by a safety concept which connects high therapeutic immunogenicity with a maximum biological safety and thus provides the condition for broad and harmless clinical application. |